Fresenius Medical Care AG &Co KG (NYSE: FMS) suffers from exceptional negative changes in investment behavior: negative upside/downside volume developed, and the stock fell on very heavy volume.
Recent significant negative changes in fundamentals have impacted Fresenius Medical Care AG &Co KG (NYSE: FMS): the consensus estimate for December, 2024 decreased significantly, and the consensus estimate for December, 2025 decreased significantly.
In light of these highly negative signals we are reviewing our current Overall Rating of C. We would view the shares with caution pending completion of this review in the next several days.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, FMS is expected to continue to be an important Value Builder.
Fresenius Medical Care AG &Co KG has a current Value Trend Rating of C (Low Neutral). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Fresenius Medical Care AG &Co KG has a good Appreciation Score of 84 but a very low Power Rating of 10, resulting in the Low Neutral Value Trend Rating.
Recent Price Action
Fresenius Medical Care AG &Co KG (NYSE: FMS) stock declined by -3.0% on 3/15/24. The shares closed at $19.04. Moreover, this decline was accompanied by exceptionally high trading volume at 339% of normal. The stock has been weak relative to the market over the last nine months and has declined -7.8% during the last week.
Be the first to comment